Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF
Author(s) -
Mohamed Hassan
Publication year - 2019
Publication title -
global cardiology science and practice
Language(s) - English
Resource type - Journals
ISSN - 2305-7823
DOI - 10.21542/gcsp.2019.3
Subject(s) - medicine , heart failure with preserved ejection fraction , cardiology , atrial fibrillation , heart failure , ejection fraction , blood pressure , observational study , pulmonary hypertension , population , disease , environmental health
[first paragraph of article] Heart failure (HF) with preserved ejection fraction (HFpEF) represents approximately 50% of the world's HF population, and this proportion is increasing over time. The diagnosis of HFpEF is more challenging than HF with reduced ejection fraction (HFrEF). Patients with HFpEF are significantly older, more likely to be female, and more likely to have hypertension, obesity, anemia, atrial fibrillation, renal disease, and pulmonary disease compared to those with HFrEF. In observational studies, rates of hospitalization and death among patients with HFpEF approach those with HFrEF, however in clinical trial populations, outcomes are better in patients who have HFpEF. Death from non- cardiovascular causes is more common in patients who have HFpEF than in those with HFrEF, and a smaller percentage of patients with HFpEF die from CVD-related causes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom